immatics is a clinical-stage biopharmaceutical company active in the discovery and development of t-cell redirecting immunotherapies for the treatment of cancer. our transformative product candidates are - best in class - adoptive cell therapies and bispecific tcr molecules. these products are directed against tumor targets that have been identified and validated by immatics' proprietary and world-leading xpresident® technology. our mission is to bring the power of t-cell redirecting immunotherapies to cancer patients. quick facts - 150 team members - >100 targets covering 20 major solid and liquid tumors - about 80% of discovered targets are novel - 2 proprietary technology platforms - 8 proprietary development programs, thereof 2 in the clinic in 2017 - multiple partnered programs - raised more than $230m in cash in five financings read more about immatics on our homepage: https://immatics.com/ find us on twitter and xing: twitter: http://bit.ly/2dfbpre xing: http://bit.ly/2e1kkpv l
Company profile
Ticker
IMTX
Exchange
Website
CEO
Harpreet Singh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Immatics B.V.
SEC CIK
IMTX stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
21 Mar 24
20-F
2023 FY
Annual report (foreign)
21 Mar 24
6-K
Immatics Announces Proposed Public Offering
22 Jan 24
424B5
Prospectus supplement for primary offering
19 Jan 24
424B5
Prospectus supplement for primary offering
17 Jan 24
6-K
Current report (foreign)
14 Nov 23
6-K
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
8 Nov 23
6-K
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
24 Oct 23
EFFECT
Notice of effectiveness
14 Sep 23
424B3
Prospectus supplement
13 Sep 23
Latest ownership filings
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
SC 13G/A
ATHOS KG
7 Feb 24
SC 13G/A
ATHOS KG
7 Feb 24
SC 13G
ATHOS KG
16 Aug 23
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 23
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 23
SC 13G/A
dievini Hopp BioTech holding GmbH & Co KG
10 Feb 23
SC 13G
WELLINGTON MANAGEMENT GROUP LLP
7 Feb 23
SC 13G
Nantahala Capital Management, LLC
14 Feb 22
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
81.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 78 |
Opened positions | 11 |
Closed positions | 5 |
Increased positions | 30 |
Reduced positions | 18 |
13F shares | Current |
---|---|
Total value | 484.79 bn |
Total shares | 68.88 mm |
Total puts | 391.80 k |
Total calls | 798.32 k |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
dievini Hopp BioTech holding GmbH & Co KG | 17.20 mm | $0.00 |
Baker Bros. Advisors | 5.64 mm | $65.32 bn |
Wellington Management | 5.61 mm | $64.91 bn |
Athos KG | 4.91 mm | $0.00 |
Arya Sciences | 3.50 mm | $37.81 mm |
Perceptive Advisors | 3.49 mm | $40.43 bn |
Sofinnova Investments | 3.25 mm | $37.65 bn |
Woodline Partners | 2.40 mm | $27.79 bn |
T. Rowe Price Investment Management | 2.23 mm | $25.76 bn |
Paradigm Biocapital Advisors | 2.06 mm | $23.84 bn |